<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="http://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="dd752f90-5b56-4d68-8896-4e363d06aa6c"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use AGGRENOX safely and effectively. See full prescribing information for AGGRENOX. <br/>
      <br/>AGGRENOXÂ® (aspirin/extended-release dipyridamole) capsules, for oral use <br/>Initial U.S. Approval: 1999</title>
   <effectiveTime value="20191219"/>
   <setId root="938ab0b5-8377-404a-8f61-5c630bda5932"/>
   <versionNumber value="18"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="603175944" root="1.3.6.1.4.1.519.1"/>
            <name>Boehringer Ingelheim Pharmaceuticals, Inc.</name>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="823f6431-3710-47d9-9186-35e0807d35ca"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20191219"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0597-0001" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Aggrenox</name>
                        <formCode code="C42916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE, EXTENDED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>aspirin and dipyridamole</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="25" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="R16CO5Y76E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ASPIRIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="R16CO5Y76E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ASPIRIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="200" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="64ALC7F90C" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DIPYRIDAMOLE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="64ALC7F90C" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DIPYRIDAMOLE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0597-0001-60" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="19991219"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0597-0001-11" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="19991219"/>
                                          <high value="20170301"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA020884" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="19991219"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48326" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RED" xsi:type="CE">
                              <originalText>red</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>ivory</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText>capsule</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="24" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">01A;</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="8a12807f-80bb-40d8-9a02-7e3d0d7a0e6d"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20191219"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%">
                           <col width="80%" align="left" valign="top"/>
                           <col width="20%" align="right" valign="bottom"/>
                           <tbody>
                              <tr>
                                 <td>Warnings and Precautions, Stress Testing with Intravenous Dipyridamole and Other Adenosinergic Agents (<linkHtml href="#S5.6">5.6</linkHtml>)</td>
                                 <td>12/2019</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="057eae04-79cc-43dc-9e87-939108ff5b35"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>AGGRENOX is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.</paragraph>
               </text>
               <effectiveTime value="20191219"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>AGGRENOX is a combination antiplatelet agent indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis (<linkHtml href="#S1">1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="aac41185-8e49-40e1-bc24-840846a5e55e"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">AGGRENOX is not interchangeable with the individual components of aspirin and dipyridamole tablets. </content>
                  </paragraph>
                  <paragraph>The recommended dose of AGGRENOX is one capsule given orally twice daily, one in the morning and one in the evening. Swallow capsules whole without chewing. AGGRENOX can be administered with or without food.</paragraph>
               </text>
               <effectiveTime value="20191219"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>One capsule twice daily (morning and evening) with or without food (<linkHtml href="#S2">2</linkHtml>)</item>
                           <item>In case of intolerable headaches during initial treatment, switch to one capsule at bedtime and low-dose aspirin in the morning; resume BID dosing within one week (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>Do not chew capsule (<linkHtml href="#S2">2</linkHtml>)</item>
                           <item>Not interchangeable with the individual components of aspirin and dipyridamole tablets (<linkHtml href="#S2">2</linkHtml>)</item>
                           <item>Dispense in this unit-of-use container (<linkHtml href="#S16">16</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="b0aa36f8-1413-46cf-acf6-79a13d41b52d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1	Alternative Regimen in Case of Intolerable Headaches</title>
                     <text>
                        <paragraph>In the event of intolerable headaches during initial treatment, switch to one capsule at bedtime and low-dose aspirin in the morning. Because there are no outcome data with this regimen and headaches become less of a problem as treatment continues, patients should return to the usual regimen as soon as possible, usually within one week.</paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="db4c9f3c-3145-4209-a928-2747f146239d"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>25 mg/200 mg capsules with a red cap and an ivory-colored body, containing yellow extended-release pellets incorporating dipyridamole and a round white tablet incorporating immediate-release aspirin. The capsule body is imprinted in red with the Boehringer Ingelheim logo and with "01A".</paragraph>
               </text>
               <effectiveTime value="20191219"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Capsule: 25 mg aspirin/200 mg extended-release dipyridamole (<linkHtml href="#S3">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="8b45452a-dd4b-421e-b1bd-9bcb268557a4"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <effectiveTime value="20191219"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Hypersensitivity to any product ingredients (<linkHtml href="#S4.1">4.1</linkHtml>)</item>
                           <item>Patients with known allergy to NSAIDs (<linkHtml href="#S4.2">4.2</linkHtml>)</item>
                           <item>Patients with the syndrome of asthma, rhinitis, and nasal polyps (<linkHtml href="#S4.2">4.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S4.1">
                     <id root="416394aa-bea7-45af-b3cc-301c4bbcea62"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.1	Hypersensitivity</title>
                     <text>
                        <paragraph>AGGRENOX is contraindicated in patients with known hypersensitivity to any of the product components.</paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                  </section>
               </component>
               <component>
                  <section ID="S4.2">
                     <id root="6d6cbdbe-472d-4ce8-84e6-191418c517e6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.2	Allergy</title>
                     <text>
                        <paragraph>Aspirin is contraindicated in patients with known allergy to nonsteroidal anti-inflammatory drug (NSAID) products and in patients with the syndrome of asthma, rhinitis, and nasal polyps. Aspirin may cause severe urticaria, angioedema or bronchospasm.</paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                  </section>
               </component>
               <component>
                  <section ID="S4.3">
                     <id root="34075f1f-f764-4469-b98b-aee90ed5ed84"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.3	Reye Syndrome</title>
                     <text>
                        <paragraph>Do not use aspirin in children or teenagers with viral infections because of the risk of Reye syndrome.</paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="44aa13b4-745e-42d8-b93c-b13789aca0ff"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20191219"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>AGGRENOX increases the risk of bleeding (<linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item>Avoid use in patients with severe hepatic or renal insufficiency (<linkHtml href="#S5.2">5.2</linkHtml>, <linkHtml href="#S5.3">5.3</linkHtml>)</item>
                           <item>Interrupt AGGRENOX capsules 48 hours before using intravenous dipyridamole or other adenosinergic agents for stress testing (<linkHtml href="#S5.6">5.6</linkHtml>, <linkHtml href="#S7.1">7.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="7dc77ba6-9d35-4826-a98a-2399606b89a7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Risk of Bleeding</title>
                     <text>
                        <paragraph>AGGRENOX increases the risk of bleeding. Risk factors for bleeding include the use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, heparin, anagrelide, fibrinolytic therapy, and chronic use of NSAIDs) <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                     <component>
                        <section>
                           <id root="03c2314c-d9f1-4eda-af41-9397a848ea00"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Intracranial Hemorrhage</content>
                              </paragraph>
                              <paragraph>In European Stroke Prevention Study-2 (ESPS2), the annualized event rate for intracranial hemorrhage was 0.39%/year in the AGGRENOX group, 0.26%/year in the extended-release dipyridamole (ER-DP) group, 0.24%/year in the aspirin (ASA) group, and 0.29%/year in the placebo groups.</paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="ef823533-1794-43a7-8d5b-616dac78a224"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Gastrointestinal (GI) Side Effects</content>
                              </paragraph>
                              <paragraph>GI side effects include stomach pain, heartburn, nausea, vomiting, and gross GI bleeding. Although minor upper GI symptoms, such as dyspepsia, are common and can occur anytime during therapy, physicians should remain alert for signs of ulceration and bleeding, even in the absence of previous GI symptoms. Inform patients about the signs and symptoms of GI side effects and what steps to take if they occur<content styleCode="italics">.</content>
                              </paragraph>
                              <paragraph>In ESPS2, the annualized event rate for gastrointestinal bleeding was 2.97%/year in the AGGRENOX group, 1.58%/year in the extended-release dipyridamole group, 2.06%/year in the aspirin group, and 1.40%/year in the placebo groups.  </paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="db116752-3e08-470f-9145-54dbaad88e39"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Peptic Ulcer Disease</content>
                              </paragraph>
                              <paragraph>Avoid using aspirin in patients with a history of active peptic ulcer disease, which can cause gastric mucosal irritation and bleeding.</paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="24c13280-7f3b-4bc7-9ec2-94f3d3897e7e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Alcohol Warning</content>
                              </paragraph>
                              <paragraph>Because AGGRENOX contains aspirin, counsel patients who consume three or more alcoholic drinks every day about the bleeding risks involved with chronic, heavy alcohol use while taking aspirin.</paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="2bd0246d-883b-4214-870b-107172ed50aa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2	Renal Failure</title>
                     <text>
                        <paragraph>Avoid aspirin in patients with severe renal failure (glomerular filtration rate less than 10 mL/minute) <content styleCode="italics">[see <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="832bb997-7ea4-4170-a4c5-98b1306add9b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	Hepatic Insufficiency</title>
                     <text>
                        <paragraph>Elevations of hepatic enzymes and hepatic failure have been reported in association with dipyridamole administration <content styleCode="italics">[see <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="a0335d72-11e1-4165-99d5-5841d3e4066c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4	Coronary Artery Disease</title>
                     <text>
                        <paragraph>Dipyridamole has a vasodilatory effect. Chest pain may be precipitated or aggravated in patients with underlying coronary artery disease who are receiving dipyridamole.</paragraph>
                        <paragraph>For stroke or TIA patients for whom aspirin is indicated to prevent recurrent myocardial infarction (MI) or angina pectoris, the aspirin in this product may not provide adequate treatment for the cardiac indications.</paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="0839ba9a-acf6-445d-b6d5-2203996c3bbb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5	Hypotension</title>
                     <text>
                        <paragraph>Dipyridamole produces peripheral vasodilation, which can exacerbate pre-existing hypotension.</paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="a14a39e9-b990-4351-b1d6-00412037f19d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6	Stress Testing with Intravenous Dipyridamole and Other Adenosinergic Agents</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Clinical experience suggests that patients being treated with AGGRENOX capsules who also require pharmacological stress testing with intravenous dipyridamole or other adenosinergic agents (e.g. adenosine, regadenoson) should interrupt AGGRENOX capsules for 48 hours prior to stress testing <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Intake of AGGRENOX capsules within 48 hours prior to stress testing with intravenous dipyridamole or other adenosinergic agents may increase the risk for cardiovascular side effects of these agents and may impair the sensitivity of the test.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.7">
                     <id root="a3ed5df3-b744-4d6f-8d9b-79424d790b1e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7	General</title>
                     <text>
                        <paragraph>AGGRENOX capsules are not interchangeable with the individual components of aspirin and dipyridamole tablets.</paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="30fac1a4-82f7-4be3-8cee-9d84187fc313"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions are discussed elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Hypersensitivity <content styleCode="italics">[see <linkHtml href="#S4.1">Contraindications (4.1)</linkHtml>]</content>
                     </item>
                     <item>Allergy <content styleCode="italics">[see <linkHtml href="#S4.2">Contraindications (4.2)</linkHtml>]</content>
                     </item>
                     <item>Risk of Bleeding <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20191219"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>The most frequently reported adverse reactions (&gt;10% and greater than placebo) were headache, dyspepsia, abdominal pain, nausea, and diarrhea (<linkHtml href="#S6.1">6.1</linkHtml>)</item>
                        </list>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc. at (800) 542-6257 or (800) 459-9906 TTY or FDA at 1-800-FDA-1088 or <content styleCode="italics">www.fda.gov/medwatch</content>.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="1b44b975-f9f4-4617-85ca-a60385ababb3"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1	Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The efficacy and safety of AGGRENOX was established in the European Stroke Prevention Study-2 (ESPS2). ESPS2 was a double-blind, placebo-controlled study that evaluated 6602 patients over the age of 18 years who had a previous ischemic stroke or transient ischemic attack within ninety days prior to entry. Patients were randomized to either AGGRENOX, aspirin, ER-DP, or placebo <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>; primary endpoints included stroke (fatal or nonfatal) and death from all causes. </paragraph>
                        <paragraph>This 24-month, multicenter, double-blind, randomized study (ESPS2) was conducted to compare the efficacy and safety of AGGRENOX with placebo, extended-release dipyridamole alone and aspirin alone. The study was conducted in a total of 6602 male and female patients who had experienced a previous ischemic stroke or transient ischemia of the brain within three months prior to randomization.  </paragraph>
                        <paragraph>Table 1 presents the annualized event rate for adverse events that occurred in 1%/year or more of patients treated with AGGRENOX where the incidence was also at least 1%/year greater than in those patients treated with placebo. There is no clear benefit of the dipyridamole/aspirin combination over aspirin with respect to safety. </paragraph>
                        <table width="95%" ID="table1">
                           <caption>Table 1	Incidence of Adverse Events in ESPS2<sup>a</sup>
                           </caption>
                           <col width="36%" align="left" valign="middle"/>
                           <col width="8%" align="left" valign="middle"/>
                           <col width="8%" align="left" valign="middle"/>
                           <col width="8%" align="left" valign="middle"/>
                           <col width="8%" align="left" valign="middle"/>
                           <col width="8%" align="left" valign="middle"/>
                           <col width="8%" align="left" valign="middle"/>
                           <col width="8%" align="left" valign="middle"/>
                           <col width="8%" align="left" valign="middle"/>
                           <thead>
                              <tr styleCode="Botrule">
                                 <th/>
                                 <th colspan="8" align="center">Individual Treatment Group</th>
                              </tr>
                              <tr>
                                 <th rowspan="2">Body System/Preferred Term</th>
                                 <th colspan="2">AGGRENOX<br/>n (%/year)<sup>b</sup>
                                 </th>
                                 <th colspan="2">ER-DP Alone<br/>n (%/year)<sup>b</sup>
                                 </th>
                                 <th colspan="2">ASA Alone<br/>n (%/year)<sup>b</sup>
                                 </th>
                                 <th colspan="2">Placebo<br/>n (%/year)<sup>b</sup>
                                 </th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" valign="top" colspan="9">
                                    <sup>a</sup>Reported by â¥1%/year of patients during AGGRENOX treatment where the incidence was at least 1%/year greater than in those treated with placebo.</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" colspan="9">
                                    <sup>b</sup>Annual event rate per 100 pt-years = 100* number of subjects with event/subject-years. Subject-years is defined as cumulative number of days on treatment divided by 365.25. </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" colspan="9">Note: ER-DP = extended-release dipyridamole 200 mg; ASA = aspirin 25 mg. The dosage regimen for all treatment groups is BID.</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" colspan="9">NOS = not otherwise specified.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td valign="bottom">
                                    <content styleCode="bold">Total Number of Patients</content>
                                 </td>
                                 <td colspan="2" valign="top">1650</td>
                                 <td colspan="2" valign="top">1654</td>
                                 <td colspan="2" valign="top">1649</td>
                                 <td colspan="2" valign="top">1649</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td valign="bottom" colspan="9">
                                    <content styleCode="bold">Central and Peripheral Nervous System Disorders</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td>Â Â Headache</td>
                                 <td>647</td>
                                 <td>(28.25)</td>
                                 <td>634</td>
                                 <td>(27.91)</td>
                                 <td>558</td>
                                 <td>(22.10)</td>
                                 <td>543</td>
                                 <td>(22.29)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td valign="bottom" colspan="9">
                                    <content styleCode="bold">Gastrointestinal System Disorders</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td>Â Â Dyspepsia</td>
                                 <td>303</td>
                                 <td>(13.23)</td>
                                 <td>288</td>
                                 <td>(12.68)</td>
                                 <td>299</td>
                                 <td>(11.84)</td>
                                 <td>275</td>
                                 <td>(11.29)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td>Â Â Abdominal Pain</td>
                                 <td>289</td>
                                 <td>(12.62)</td>
                                 <td>255</td>
                                 <td>(11.22)</td>
                                 <td>262</td>
                                 <td>(10.38)</td>
                                 <td>239</td>
                                 <td>(9.81)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td>Â Â Nausea</td>
                                 <td>264</td>
                                 <td>(11.53)</td>
                                 <td>254</td>
                                 <td>(11.18)</td>
                                 <td>210</td>
                                 <td>(8.32)</td>
                                 <td>232</td>
                                 <td>(9.53)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td>Â Â Diarrhea</td>
                                 <td>210</td>
                                 <td>(9.17)</td>
                                 <td>257</td>
                                 <td>(11.31)</td>
                                 <td>112</td>
                                 <td>(4.44)</td>
                                 <td>161</td>
                                 <td>(6.61)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td>Â Â Vomiting</td>
                                 <td>138</td>
                                 <td>(6.03)</td>
                                 <td>129</td>
                                 <td>(5.68)</td>
                                 <td>101</td>
                                 <td>(4.00)</td>
                                 <td>118</td>
                                 <td>(4.84)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td valign="bottom" colspan="9">
                                    <content styleCode="bold">Platelet, Bleeding and Clotting Disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>Â Â Hemorrhage NOS</td>
                                 <td>52</td>
                                 <td>(2.27)</td>
                                 <td>24</td>
                                 <td>(1.06)</td>
                                 <td>46</td>
                                 <td>(1.82)</td>
                                 <td>24</td>
                                 <td>(0.99)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Discontinuation due to adverse events in ESPS2 was 25% for AGGRENOX, 25% for extended-release dipyridamole, 19% for aspirin, and 21% for placebo (refer to Table 2).</paragraph>
                        <table width="95%" ID="table2">
                           <caption>Table 2	Incidence of Adverse Events that Led to the Discontinuation of Treatment<sup>a</sup>
                           </caption>
                           <col width="36%" align="left" valign="top"/>
                           <col width="8%" align="left" valign="top"/>
                           <col width="8%" align="left" valign="top"/>
                           <col width="8%" align="left" valign="top"/>
                           <col width="8%" align="left" valign="top"/>
                           <col width="8%" align="left" valign="top"/>
                           <col width="8%" align="left" valign="top"/>
                           <col width="8%" align="left" valign="top"/>
                           <col width="8%" align="left" valign="top"/>
                           <thead>
                              <tr>
                                 <th/>
                                 <th colspan="8" styleCode="Botrule" align="center">Treatment Groups</th>
                              </tr>
                              <tr>
                                 <th/>
                                 <th colspan="2" align="center">AGGRENOX<br/>n (%/year)<sup>b</sup>
                                 </th>
                                 <th colspan="2" align="center">ER-DP<br/>n (%/year)<sup>b</sup>
                                 </th>
                                 <th colspan="2" align="center">ASA<br/>n (%/year)<sup>b</sup>
                                 </th>
                                 <th colspan="2" align="center">Placebo<br/>n (%/year)<sup>b</sup>
                                 </th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="9" align="left" valign="top">
                                    <sup>a</sup>Reported by â¥1%/year of patients during AGGRENOX treatment where the incidence was at least 1%/year greater than in those treated with placebo.</td>
                              </tr>
                              <tr>
                                 <td colspan="9" align="left" valign="top">
                                    <sup>b</sup>Annual event rate per 100 pt-years = 100* number of subjects with event/subject-years. Subject-years is defined as cumulative number of days on treatment divided by 365.25. </td>
                              </tr>
                              <tr>
                                 <td colspan="9" align="left" valign="top">Note: ER-DP = extended-release dipyridamole 200 mg; ASA = aspirin 25 mg. The dosage regimen for all treatment groups is BID.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td>
                                    <content styleCode="bold">Total Number of Patients</content>
                                 </td>
                                 <td colspan="2" align="center">1650</td>
                                 <td colspan="2" align="center">1654</td>
                                 <td colspan="2" align="center">1649</td>
                                 <td colspan="2" align="center">1649</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td valign="bottom">
                                    <content styleCode="bold">Patients with at least one Adverse Event that led to treatment discontinuation</content>
                                 </td>
                                 <td valign="bottom">417</td>
                                 <td valign="bottom">(18.21)</td>
                                 <td valign="bottom">419</td>
                                 <td valign="bottom">(18.44)</td>
                                 <td valign="bottom">318</td>
                                 <td valign="bottom">(12.59)</td>
                                 <td valign="bottom">352</td>
                                 <td valign="bottom">(14.45)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td>Headache</td>
                                 <td>165</td>
                                 <td>(7.20)</td>
                                 <td>166</td>
                                 <td>(7.31)</td>
                                 <td>57</td>
                                 <td>(2.26)</td>
                                 <td>69</td>
                                 <td>(2.83)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td>Nausea</td>
                                 <td>91</td>
                                 <td>(3.97)</td>
                                 <td>95</td>
                                 <td>(4.18)</td>
                                 <td>51</td>
                                 <td>(2.02)</td>
                                 <td>53</td>
                                 <td>(2.18)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td>Abdominal Pain</td>
                                 <td>74</td>
                                 <td>(3.23)</td>
                                 <td>64</td>
                                 <td>(2.82)</td>
                                 <td>56</td>
                                 <td>(2.22)</td>
                                 <td>52</td>
                                 <td>(2.13)</td>
                              </tr>
                              <tr>
                                 <td>Vomiting</td>
                                 <td>53</td>
                                 <td>(2.31)</td>
                                 <td>52</td>
                                 <td>(2.29)</td>
                                 <td>28</td>
                                 <td>(1.11)</td>
                                 <td>24</td>
                                 <td>(0.99)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Headache was most notable in the first month of treatment.</paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="849ebf8d-5088-4d7e-af85-d14fc43c97c2"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2	Post-Marketing Experience</title>
                     <text>
                        <paragraph>The following is a list of additional adverse reactions that have been reported either in the literature or are from post-marketing spontaneous reports for either dipyridamole or aspirin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of reporting, or (3) strength of causal connection to AGGRENOX.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Body as a Whole:</content> Hypothermia, chest pain, allergic reaction, syncope</paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiovascular:</content> Angina pectoris, hypotension </paragraph>
                        <paragraph>
                           <content styleCode="italics">Central Nervous System:</content> Cerebral edema, dizziness, cerebral hemorrhage, intracranial hemorrhage, subarachnoid hemorrhage </paragraph>
                        <paragraph>
                           <content styleCode="italics">Fluid and Electrolyte:</content> Hyperkalemia, metabolic acidosis, respiratory alkalosis, hypokalemia  </paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal:</content> Pancreatitis, Reye syndrome, hematemesis, gastritis, ulceration and perforation, hemorrhage rectum, melena, GI hemorrhage </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hearing and Vestibular Disorders:</content> Hearing loss</paragraph>
                        <paragraph>
                           <content styleCode="italics">Heart Rate and Rhythm Disorders:</content> Tachycardia, palpitation  </paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune System Disorders:</content> Hypersensitivity, acute anaphylaxis, laryngeal edema   </paragraph>
                        <paragraph>
                           <content styleCode="italics">Liver and Biliary System Disorders:</content> Hepatitis, hepatic failure, cholelithiasis, jaundice, hepatic function abnormal  </paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal:</content> Rhabdomyolysis, myalgia </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolic and Nutritional Disorders:</content> Hypoglycemia, dehydration</paragraph>
                        <paragraph>
                           <content styleCode="italics">Platelet, Bleeding and Clotting Disorders:</content> Prolongation of the prothrombin time, disseminated intravascular coagulation, coagulopathy, thrombocytopenia, hematoma, gingival bleeding, epistaxis, purpura </paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric Disorders:</content> Confusion, agitation</paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory:</content> Tachypnea, dyspnea, hemoptysis   </paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and Appendages Disorders:</content> Rash, alopecia, angioedema, Stevens-Johnson syndrome, skin hemorrhages such as bruising, ecchymosis, and hematoma, pruritus, urticaria </paragraph>
                        <paragraph>
                           <content styleCode="italics">Urogenital:</content> Interstitial nephritis, papillary necrosis, proteinuria, renal insufficiency and failure, hematuria </paragraph>
                        <paragraph>
                           <content styleCode="italics">Vascular (Extracardiac) Disorders:</content> Allergic vasculitis, flushing</paragraph>
                        <paragraph>
                           <content styleCode="italics">Other Adverse Events:</content> Anorexia, aplastic anemia, migraine, pancytopenia, thrombocytosis.</paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="6e5b1773-ec87-40fa-9298-c65db67a216a"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20191219"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Co-administration with anticoagulants, antiplatelets, or NSAIDs can increase risk of bleeding (<linkHtml href="#S7.1">7.1</linkHtml>)</item>
                           <item>Decreased renal function can occur with co-administration with NSAIDs (<linkHtml href="#S7.1">7.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="d377fd74-2236-4493-8910-59322d676c47"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1	Drug Interaction Study Information Obtained From Literature</title>
                     <effectiveTime value="20191219"/>
                     <component>
                        <section>
                           <id root="8472e07d-4fad-4f37-802b-85b19f638f4d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Adenosinergic agents (e.g. adenosine, regadenoson)</content>
                              </paragraph>
                              <paragraph>Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be necessary. Dipyridamole also increases the cardiovascular effects of regadenoson, an adenosine A<sub>2A</sub>-receptor agonist. The potential risk of cardiovascular side effects with intravenous adenosinergic agents may be increased during the testing period when dipyridamole is not held 48 hours prior to stress testing.</paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2836ac46-6a3b-4cd1-b575-f4f60492835d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Angiotensin Converting Enzyme (ACE) Inhibitors</content>
                              </paragraph>
                              <paragraph>Because of the indirect effect of aspirin on the renin-angiotensin conversion pathway, the hyponatremic and hypotensive effects of ACE inhibitors may be diminished by concomitant administration of aspirin.</paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="f684564f-3e79-48ba-8491-bea5b9a18d2a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Acetazolamide</content>
                              </paragraph>
                              <paragraph>Concurrent use of aspirin and acetazolamide can lead to high serum concentrations of acetazolamide (and toxicity) due to competition at the renal tubule for secretion.</paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="01977e23-6b47-4a6a-8b1a-c3957c9bd8ce"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Anticoagulants and Antiplatelets</content>
                              </paragraph>
                              <paragraph>Patients taking AGGRENOX in combination with anticoagulants, antiplatelets, or any substance impacting coagulation are at increased risk for bleeding. Aspirin can displace warfarin from protein binding sites, leading to prolongation of both the prothrombin time and the bleeding time. Aspirin can increase the anticoagulant activity of heparin, increasing bleeding risk.</paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="79c87b33-0f8d-4e11-a938-8264ef4a6f5a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Anagrelide</content>
                              </paragraph>
                              <paragraph>Patients taking aspirin in combination with anagrelide are at an increased risk of bleeding. </paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="fefcbf5e-eb17-4b18-885c-b6f4c4f6588a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Anticonvulsants</content>
                              </paragraph>
                              <paragraph>Salicylic acid can displace protein-bound phenytoin and valproic acid, leading to a decrease in the total concentration of phenytoin and an increase in serum valproic acid levels. </paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="8444d01a-60ff-4caf-bb83-5045f9f4f3d7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Beta Blockers</content>
                              </paragraph>
                              <paragraph>The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid retention.</paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="811ecca8-2ee7-41e8-af08-e7a8421c748c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Cholinesterase Inhibitors</content>
                              </paragraph>
                              <paragraph>Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis.</paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="57e7eb34-fcc0-4927-9889-330f096b277b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Diuretics</content>
                              </paragraph>
                              <paragraph>The effectiveness of diuretics in patients with underlying renal or cardiovascular disease may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid retention.</paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="e01ae1f4-2430-4dc2-b2ce-bd048269557e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Methotrexate</content>
                              </paragraph>
                              <paragraph>Salicylate can inhibit renal clearance of methotrexate, leading to bone marrow toxicity, especially in the elderly or renal impaired.</paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="e633f3f4-381a-4576-aa54-c43269f747a4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)</content>
                              </paragraph>
                              <paragraph>The concurrent use of aspirin with other NSAIDs may increase bleeding or lead to decreased renal function.</paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="06f207b9-293b-4e8b-b4d6-024879605c9b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Oral Hypoglycemics</content>
                              </paragraph>
                              <paragraph>Moderate doses of aspirin may increase the effectiveness of oral hypoglycemic drugs, leading to hypoglycemia.</paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="33c50d34-22d2-44f5-880c-437d1f00b0f8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Uricosuric Agents (probenecid and sulfinpyrazone)</content>
                              </paragraph>
                              <paragraph>Salicylates antagonize the uricosuric action of uricosuric agents.</paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="4907e55c-5738-4c0b-beae-2b5bf7e7087f"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20191219"/>
               <component>
                  <section ID="S8.1">
                     <id root="7064a9b1-36f7-455e-bce5-9d5354c011e4"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20191219"/>
                     <component>
                        <section>
                           <id root="09822f05-895f-41a1-81b9-60ff1d787443"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Available data from published studies and postmarketing experience with AGGRENOX use during pregnancy have not identified a clear association between AGGRENOX use and major birth defects, miscarriage, or adverse maternal or fetal outcomes <content styleCode="italics">(see <linkHtml href="#data">Data</linkHtml>)</content>. AGGRENOX contains low-dose aspirin which is an NSAID <content styleCode="italics">(see <linkHtml href="#cc">Clinical Considerations</linkHtml>)</content>. In animal reproduction studies, there were adverse developmental effects with administration of aspirin in rats and rabbits at doses about 66 and 44 times, respectively, the human exposure at the maximum recommended daily dose of aspirin-dipyridamole. Reproduction studies with dipyridamole in mice, rabbits, and rats have revealed no evidence of harm to the fetus up to doses about 25 times the maximum recommended daily human dose of aspirin-dipyridamole. Nonclinical data are suggestive of a possible potentiation of aspirin-related fetal toxicity when combined with dipyridamole <content styleCode="italics">(see <linkHtml href="#data">Data</linkHtml>)</content>.</paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4 and 15-20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                        </section>
                     </component>
                     <component>
                        <section ID="cc">
                           <id root="bcc4ee0c-a11a-43f6-83ae-e5693c27e2d5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                           <component>
                              <section>
                                 <id root="5e4b1bf6-5563-4b6d-8cf1-01940251ebba"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Labor and Delivery</content>
                                    </paragraph>
                                    <paragraph>AGGRENOX, which contains dipyridamole and low-dose aspirin, increases the risk for bleeding <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].</content> Maternal use of high-dose aspirin can result in excessive blood loss at delivery, prolonged gestation, prolonged labor, intracranial hemorrhage in premature infants, low birth weight, stillbirth, and neonatal death. </paragraph>
                                 </text>
                                 <effectiveTime value="20191219"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="data">
                           <id root="3add5905-6349-4529-87ad-7c77550a3d0b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                           <component>
                              <section>
                                 <id root="41fdd3b4-c351-468e-9f37-deea4613a5df"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Human Data</content>
                                    </paragraph>
                                    <paragraph>Published data from clinical trials, observational studies, case series, and case reports over several decades have not identified a clear association between aspirin-dipyridamole use in pregnancy and major birth defects, miscarriage, or adverse maternal or fetal outcomes. However, these studies cannot definitively establish the absence of any aspirin-dipyridamole associated risks. Methodological limitations of these studies include variability in the timing and dose of drug exposure (e.g., most exposures occurred beyond the first trimester) and the small sample sizes of individual studies.</paragraph>
                                 </text>
                                 <effectiveTime value="20191219"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="991370a0-e5ac-4391-911d-188d78ac5303"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Aspirin has been shown to be teratogenic in rats (spina bifida, exencephaly, microphthalmia and coelosomia) and rabbits (congested fetuses, agenesis of skull and upper jaw, generalized edema with malformation of the head, and diaphanous skin) at oral doses of 330 mg/kg/day and 110 mg/kg/day, respectively. These doses, which also resulted in a high resorption rate in rats (63% of implantations versus 5% in controls), are, on a mg/m<sup>2</sup> basis, about 66 and 44 times, respectively, the dose of aspirin contained in the maximum recommended daily human dose of aspirin-dipyridamole. Reproduction studies with dipyridamole have been performed in mice, rabbits and rats at oral doses of up to 125 mg/kg, 40 mg/kg, and 1000 mg/kg, respectively (about 1Â½, 2, and 25 times the maximum recommended daily human oral dose, respectively, on a mg/m<sup>2</sup> basis) and have revealed no evidence of harm to the fetus due to dipyridamole. When 330 mg aspirin/kg/day was combined with 75 mg dipyridamole/kg/day in the rat at doses about 66 and 2 times, respectively, the maximum recommended daily human dose, the resorption rate approached 100%.</paragraph>
                                 </text>
                                 <effectiveTime value="20191219"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="e77d80a5-f6cb-4047-8040-6f7b08f6a41b"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20191219"/>
                     <component>
                        <section>
                           <id root="189e2eab-b303-4c61-ab64-2d7f345e579e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Based on data from a clinical lactation study in breastfeeding women taking low-dose aspirin, the metabolite salicylic acid is present in human milk in low levels <content styleCode="italics">(see <linkHtml href="#data2">Data</linkHtml>)</content>. Dipyridamole is also present in human milk. There is no information on the effects of AGGRENOX or dipyridamole on the breastfed infant or on milk production. There is insufficient information to determine the effects of aspirin on the breastfed infant and no information on the effects of aspirin on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for AGGRENOX and any potential adverse effects on the breastfed child from AGGRENOX or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                        </section>
                     </component>
                     <component>
                        <section ID="data2">
                           <id root="05b0a79c-90ff-459a-bc49-075f1db7487d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                              <paragraph>A published clinical study involved six exclusively breastfeeding women at 1 to 8 months postpartum who were taking 81 mg aspirin daily. Milk samples were collected at steady state, at 0, 1, 2, 4, 8, 12, and 24 hours after taking a dose of aspirin. Aspirin was undetectable in human milk. Salicylic acid was present in milk at low levels (average concentration of 24 ng/mL). Based on an average milk consumption of 150 mL/kg/day, the calculated relative infant dose was 0.4%. No adverse effects on the breastfed infants were noted.</paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="b5ea656b-04df-4ac3-a52c-37355a877d42"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness of AGGRENOX in pediatric patients have not been studied. Because of the aspirin component, use of this product in the pediatric population is not recommended <content styleCode="italics">[see <linkHtml href="#S4.3">Contraindications (4.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="f4e210c8-142b-4510-9881-be0099447f0d"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Of the total number of subjects in ESPS2, 61% were 65 and over, while 27% were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="a8181113-53ef-4150-b918-72339e0fe776"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6	Patients with Severe Hepatic or Severe Renal Dysfunction</title>
                     <text>
                        <paragraph>AGGRENOX has not been studied in patients with hepatic or renal impairment. Avoid using aspirin containing products, such as AGGRENOX, in patients with severe hepatic or severe renal (glomerular filtration rate &lt;10 mL/min) dysfunction <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2</linkHtml>, <linkHtml href="#S5.3">5.3)</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="36a29f32-1317-45cb-a992-526333406a2b"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Because of the dose ratio of dipyridamole to aspirin, overdosage of AGGRENOX is likely to be dominated by signs and symptoms of dipyridamole overdose. In case of real or suspected overdose, seek medical attention or contact a Poison Control Center immediately. Careful medical management is essential.</paragraph>
                  <paragraph>Based upon the known hemodynamic effects of dipyridamole, symptoms such as warm feeling, flushes, sweating, restlessness, feeling of weakness, and dizziness may occur. A drop in blood pressure and tachycardia might also be observed.</paragraph>
                  <paragraph>Salicylate toxicity may result from acute ingestion (overdose) or chronic intoxication. Severity of aspirin intoxication is determined by measuring the blood salicylate level. The early signs of salicylic overdose (salicylism), including tinnitus (ringing in the ears), occur at plasma concentrations approaching 200 Âµg/mL. In severe cases, hyperthermia and hypovolemia are the major immediate threats to life. Plasma concentrations of aspirin above 300 Âµg/mL are clearly toxic. Severe toxic effects are associated with levels above 400 Âµg/mL. A single lethal dose of aspirin in adults is not known with certainty but death may be expected at 30 g.</paragraph>
                  <paragraph>Treatment of overdose consists primarily of supporting vital functions, increasing drug elimination, and correcting acid-base disturbances. Consider gastric emptying and/or lavage as soon as possible after ingestion, even if the patient has vomited spontaneously. After lavage and/or emesis, administration of activated charcoal as a slurry may be beneficial if less than 3 hours have passed since ingestion. Charcoal absorption should not be employed prior to emesis and lavage. Follow acid-base status closely with serial blood gas and serum pH measurements. Maintain fluid and electrolyte balance. Administer replacement fluid intravenously and augment with correction of acidosis. Treatment may require the use of a vasopressor. Infusion of glucose may be required to control hypoglycemia.</paragraph>
                  <paragraph>Administration of xanthine derivatives (e.g., aminophylline) may reverse the vasodilatory effects of dipyridamole overdose. Plasma electrolytes and pH should be monitored serially to promote alkaline diuresis of salicylate if renal function is normal. In patients with renal insufficiency or in cases of life-threatening intoxication, dialysis is usually required to treat salicylic overdose; however, since dipyridamole is highly protein bound, dialysis is not likely to remove dipyridamole. Exchange transfusion may be indicated in infants and young children.</paragraph>
               </text>
               <effectiveTime value="20191219"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="f0f9c901-8cfe-432d-8a14-f0d23d6faff2"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>AGGRENOX is a combination antiplatelet agent intended for oral administration. Each hard gelatin capsule contains 200 mg dipyridamole in an extended-release form and 25 mg aspirin, as an immediate-release sugar-coated tablet. In addition, each capsule contains the following inactive ingredients: acacia, aluminum stearate, colloidal silicon dioxide, corn starch, dimethicone, hypromellose, hypromellose phthalate, lactose monohydrate, methacrylic acid copolymer, microcrystalline cellulose, povidone, stearic acid, sucrose, talc, tartaric acid, titanium dioxide, and triacetin.</paragraph>
                  <paragraph>Each capsule shell contains gelatin, red iron oxide and yellow iron oxide, titanium dioxide, and water.</paragraph>
               </text>
               <effectiveTime value="20191219"/>
               <component>
                  <section>
                     <id root="770a847b-884b-4251-861e-d99412041dd9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Dipyridamole</content>
                        </paragraph>
                        <paragraph>Dipyridamole is an antiplatelet agent chemically described as 2,2',2'',2'''-[(4,8-Dipiperidinopyrimido[5,4-<content styleCode="italics">d</content>]pyrimidine-2,6-diyl)dinitrilo]-tetraethanol. It has the following structural formula:</paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM1"/>
                        </paragraph>
                        <paragraph>C<sub>24</sub>H<sub>40</sub>N<sub>8</sub>O<sub>4</sub>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Mol. Wt. 504.63</paragraph>
                        <paragraph>Dipyridamole is an odorless yellow crystalline substance, having a bitter taste. It is soluble in dilute acids, methanol and chloroform, and is practically insoluble in water.</paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                     <component>
                        <observationMedia ID="MM1">
                           <text>Chemical Structure</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="aggrenox-01.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="41564d61-e245-4bf3-9e0a-c9345fd7cf11"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Aspirin</content>
                        </paragraph>
                        <paragraph>The antiplatelet agent aspirin (acetylsalicylic acid) is chemically known as benzoic acid, 2- (acetyloxy)-, and has the following structural formula:</paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM2"/>
                        </paragraph>
                        <paragraph>C<sub>9</sub>H<sub>8</sub>O<sub>4</sub>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Mol. Wt. 180.16</paragraph>
                        <paragraph>Aspirin is an odorless white needle-like crystalline or powdery substance. When exposed to moisture, aspirin hydrolyzes into salicylic and acetic acids, and gives off a vinegary odor. It is highly lipid soluble and slightly soluble in water.</paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                     <component>
                        <observationMedia ID="MM2">
                           <text>Chemical Structure</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="aggrenox-02.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="f3fb3f8d-b77a-496f-acff-bb0b61b9d20a"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20191219"/>
               <component>
                  <section ID="S12.1">
                     <id root="0ddbef85-e574-4d73-bc00-e6d67cc7f005"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>The antithrombotic action of AGGRENOX is the result of the additive antiplatelet effects of dipyridamole and aspirin.</paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                     <component>
                        <section>
                           <id root="1591b33e-d624-475e-b25b-3887b86007e4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Dipyridamole</content>
                              </paragraph>
                              <paragraph>Dipyridamole inhibits the uptake of adenosine into platelets, endothelial cells and erythrocytes <content styleCode="italics">in vitro</content> and <content styleCode="italics">in vivo</content>; the inhibition occurs in a dose-dependent manner at therapeutic concentrations (0.5â1.9 Âµg/mL). This inhibition results in an increase in local concentrations of adenosine which acts on the platelet A<sub>2</sub>-receptor thereby stimulating platelet adenylate cyclase and increasing platelet cyclic-3',5'-adenosine monophosphate (cAMP) levels. Via this mechanism, platelet aggregation is inhibited in response to various stimuli such as platelet activating factor (PAF), collagen and adenosine diphosphate (ADP). </paragraph>
                              <paragraph>Dipyridamole inhibits phosphodiesterase (PDE) in various tissues. While the inhibition of cAMP-PDE is weak, therapeutic levels of dipyridamole inhibit cyclic-3',5'-guanosine monophosphate-PDE (cGMP-PDE), thereby augmenting the increase in cGMP produced by EDRF (endothelium-derived relaxing factor, now identified as nitric oxide).  </paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="f7f16eaa-938b-4acf-9c99-b866db027650"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Aspirin</content>
                              </paragraph>
                              <paragraph>Aspirin inhibits platelet aggregation by irreversible inhibition of platelet cyclooxygenase and thus inhibits the generation of thromboxane A<sub>2</sub>, a powerful inducer of platelet aggregation and vasoconstriction. </paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="8017036f-be41-4552-937c-bb3467a42d3b"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>The effect of either agent on the other's inhibition of platelet reactivity has not been evaluated.</paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="0d4424bc-ef10-4253-aec2-a916adba4fec"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>There are no significant interactions between aspirin and dipyridamole. The kinetics of the components are unchanged by their co-administration as AGGRENOX. </paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                     <component>
                        <section>
                           <id root="7280c2fc-cb48-4072-895d-be6e3eb5882c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                           <component>
                              <section>
                                 <id root="2bfc33f1-4e58-4efe-8174-b05b38886f04"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Dipyridamole:</content>
                                    </paragraph>
                                    <paragraph>Peak plasma levels of dipyridamole are achieved 2 hours (range 1â6 hours) after administration of a daily dose of 400 mg AGGRENOX (given as 200 mg BID). The peak plasma concentration at steady-state is 1.98 Âµg/mL (1.01â3.99 Âµg/mL) and the steady-state trough concentration is 0.53 Âµg/mL (0.18â1.01 Âµg/mL). </paragraph>
                                 </text>
                                 <effectiveTime value="20191219"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="9654e2f3-b982-47a8-aba7-0a0cb760a4b9"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Aspirin:</content>
                                    </paragraph>
                                    <paragraph>Peak plasma levels of aspirin are achieved 0.63 hours (0.5â1 hour) after administration of a 50 mg aspirin daily dose from AGGRENOX (given as 25 mg BID). The peak plasma concentration at steady-state is 319 ng/mL (175â463 ng/mL). Aspirin undergoes moderate hydrolysis to salicylic acid in the liver and the gastrointestinal wall, with 50%â75% of an administered dose reaching the systemic circulation as intact aspirin.</paragraph>
                                 </text>
                                 <effectiveTime value="20191219"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="cc42e825-c4d1-4061-85ae-9fd138732311"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Effect of Food</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                           <component>
                              <section>
                                 <id root="b9be49ce-29bc-4b61-8dd9-ae78be54e2a0"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Dipyridamole:</content>
                                    </paragraph>
                                    <paragraph>When AGGRENOX capsules were taken with a high fat meal, dipyridamole peak plasma levels (C<sub>max</sub>) and total absorption (AUC) were decreased at steady-state by 20-30% compared to fasting. Due to the similar degree of inhibition of adenosine uptake at these plasma concentrations, this food effect is not considered clinically relevant.</paragraph>
                                 </text>
                                 <effectiveTime value="20191219"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="ab9971c4-9d30-4331-8d36-07ccb4a0191a"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Aspirin:</content>
                                    </paragraph>
                                    <paragraph>When AGGRENOX capsules were taken with a high fat meal, there was no difference for aspirin in AUC at steady-state, and the approximately 50% decrease in C<sub>max</sub> was not considered clinically relevant based on a similar degree of cyclooxygenase inhibition comparing the fed and fasted state.</paragraph>
                                 </text>
                                 <effectiveTime value="20191219"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="01abd4aa-5ed7-4614-afae-4ff2db150c5e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                           <component>
                              <section>
                                 <id root="300acfd9-320a-4285-b462-4b81ec03b85b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Dipyridamole:</content>
                                    </paragraph>
                                    <paragraph>Dipyridamole is highly lipophilic (log P=3.71, pH=7); however, it has been shown that the drug does not cross the blood-brain barrier to any significant extent in animals. The steady-state volume of distribution of dipyridamole is about 92 L. Approximately 99% of dipyridamole is bound to plasma proteins, predominantly to alpha 1-acid glycoprotein and albumin.</paragraph>
                                 </text>
                                 <effectiveTime value="20191219"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="177ec949-154c-4f27-9850-a24bc5c8666c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Aspirin:</content>
                                    </paragraph>
                                    <paragraph>Aspirin is poorly bound to plasma proteins and its apparent volume of distribution is low (10 L). Its metabolite, salicylic acid, is highly bound to plasma proteins, but its binding is concentration-dependent (nonlinear). At low concentrations (&lt;100 mcg/mL), approximately 90% of salicylic acid is bound to albumin. Salicylic acid is widely distributed to all tissues and fluids in the body, including the central nervous system, breast milk, and fetal tissues. Early signs of salicylate overdose (salicylism), including tinnitus (ringing in the ears), occur at plasma concentrations approximating 200 mcg/mL <content styleCode="italics">[see <linkHtml href="#S10">Overdosage (10)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20191219"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="27cece07-4f9a-4ba6-bbcd-72c3a3ad4af1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Metabolism and Elimination</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                           <component>
                              <section>
                                 <id root="eed98d4e-431d-4317-8631-bd93955c02f5"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Dipyridamole:</content>
                                    </paragraph>
                                    <paragraph>Dipyridamole is metabolized in the liver, primarily by conjugation with glucuronic acid, of which monoglucuronide which has low pharmacodynamic activity is the primary metabolite. In plasma, about 80% of the total amount is present as parent compound and 20% as monoglucuronide. Most of the glucuronide metabolite (about 95%) is excreted via bile into the feces, with some evidence of enterohepatic circulation. Renal excretion of parent compound is negligible and urinary excretion of the glucuronide metabolite is low (about 5%). With intravenous (i.v.) treatment of dipyridamole, a triphasic profile is obtained: a rapid alpha phase, with a half-life of about 3.4 minutes, a beta phase, with a half-life of about 39 minutes, (which, together with the alpha phase accounts for about 70% of the total area under the curve, AUC) and a prolonged elimination phase Î»<sub>z</sub> with a half-life of about 15.5 hours. Because of the extended absorption phase of the dipyridamole component, only the terminal phase is apparent from oral treatment with AGGRENOX which was 13.6 hours.</paragraph>
                                 </text>
                                 <effectiveTime value="20191219"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="c60bb04d-d7c8-47ed-9ac8-0cfe43d1c7f7"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Aspirin:</content>
                                    </paragraph>
                                    <paragraph>Aspirin is rapidly hydrolyzed in plasma to salicylic acid, with a half-life of 20 minutes. Plasma levels of aspirin are essentially undetectable 2â2.5 hours after dosing and peak salicylic acid concentrations occur 1 hour (range: 0.5â2 hours) after administration of aspirin. Salicylic acid is primarily conjugated in the liver to form salicyluric acid, a phenolic glucuronide, an acyl glucuronide, and a number of minor metabolites. Salicylate metabolism is saturable and total body clearance decreases at higher serum concentrations due to the limited ability of the liver to form both salicyluric acid and phenolic glucuronide. Following toxic doses (10â20 g), the plasma half-life may be increased to over 20 hours.</paragraph>
                                    <paragraph>The elimination of acetylsalicylic acid follows first-order kinetics with AGGRENOX and has a half-life of 0.33 hours. The half-life of salicylic acid is 1.71 hours. Both values correspond well with data from the literature at lower doses which state a resultant half-life of approximately 2â3 hours. At higher doses, the elimination of salicylic acid follows zero-order kinetics (i.e., the rate of elimination is constant in relation to plasma concentration), with an apparent half-life of 6 hours or higher. Renal excretion of unchanged drug depends upon urinary pH. As urinary pH rises above 6.5, the renal clearance of free salicylate increases from &lt;5% to &gt;80%. Alkalinization of the urine is a key concept in the management of salicylate overdose <content styleCode="italics">[see <linkHtml href="#S10">Overdosage (10)</linkHtml>]</content>. Following therapeutic doses, about 10% is excreted as salicylic acid and 75% as salicyluric acid, as the phenolic and acyl glucuronides, in urine.</paragraph>
                                 </text>
                                 <effectiveTime value="20191219"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="4799781a-f9c6-473d-ad6b-077a884d5067"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                           <component>
                              <section>
                                 <id root="94e4424c-5363-4ba1-9ccf-92001f771c61"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline italics">Geriatric Patients:</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20191219"/>
                                 <component>
                                    <section>
                                       <id root="779df54c-10ea-4139-8cf8-80980ee10357"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Dipyridamole:</content>
                                          </paragraph>
                                          <paragraph>In ESPS2 <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>, plasma concentrations (determined as AUC) of dipyridamole in healthy elderly subjects (&gt;65 years) were about 40% higher than in subjects younger than 55 years receiving treatment with AGGRENOX. </paragraph>
                                       </text>
                                       <effectiveTime value="20191219"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="8e81204c-bf15-4255-a0f1-4aae4736a8f1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline italics">Hepatic Dysfunction:</content>
                                    </paragraph>
                                    <paragraph>No study has been conducted with AGGRENOX in patients with hepatic dysfunction.</paragraph>
                                 </text>
                                 <effectiveTime value="20191219"/>
                                 <component>
                                    <section>
                                       <id root="4073bde9-fadc-46e7-ba9e-68781c8f4e45"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Dipyridamole:</content>
                                          </paragraph>
                                          <paragraph>In a study conducted with an intravenous formulation of dipyridamole, patients with mild to severe hepatic insufficiency showed no change in plasma concentrations of dipyridamole but showed an increase in the pharmacologically inactive monoglucuronide metabolite. Dipyridamole can be dosed without restriction as long as there is no evidence of hepatic failure.</paragraph>
                                       </text>
                                       <effectiveTime value="20191219"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="d99521c8-9add-4e2a-a047-03c439fb9c01"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Aspirin:</content>
                                          </paragraph>
                                          <paragraph>Avoid aspirin in patients with severe hepatic insufficiency.</paragraph>
                                       </text>
                                       <effectiveTime value="20191219"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3305ada5-5b3c-42e6-ae52-08fe86606c19"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline italics">Renal Dysfunction:</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20191219"/>
                                 <component>
                                    <section>
                                       <id root="3bd94ff7-a1c2-475f-a86a-e2c9ddb27754"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Dipyridamole:</content>
                                          </paragraph>
                                          <paragraph>In ESPS2 patients <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>, with creatinine clearances ranging from about 15 mL/min to &gt;100 mL/min, no changes were observed in the pharmacokinetics of dipyridamole or its glucuronide metabolite if data were corrected for differences in age. </paragraph>
                                       </text>
                                       <effectiveTime value="20191219"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="7a43080d-1f1b-4d64-89a2-022177f55820"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Aspirin:</content>
                                          </paragraph>
                                          <paragraph>Avoid aspirin in patients with severe renal failure (glomerular filtration rate &lt;10 mL/min).</paragraph>
                                       </text>
                                       <effectiveTime value="20191219"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="7b62a2a8-1b92-4ff8-96cd-e3cfcd8afcdc"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                              <paragraph>A dedicated drug interaction study was conducted in 60 healthy volunteers to evaluate the effects of omeprazole 80 mg administered once daily on the pharmacokinetics (PK) of dipyridamole and the pharmacodynamics (PD) of acetylsalicylic acid when co-administered with AGGRENOX twice daily. Dipyridamole exposure (C<sub>max</sub> and AUC) at steady-state were similar with or without omeprazole co-administration. The pharmacokinetics of acetylsalicylic acid was not characterized. However, the antiplatelet activity as measured by arachidonic acid induced platelet aggregation was similar between the treatment arms at steady-state.</paragraph>
                           </text>
                           <effectiveTime value="20191219"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="8b51e13c-294a-4406-a402-9856dc8b4aa2"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20191219"/>
               <component>
                  <section ID="S13.1">
                     <id root="f36cd89e-0ad2-4c55-8e8f-02ab9a792a88"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>In studies in which dipyridamole was administered in the feed to mice (up to 111 weeks in males and females) and rats (up to 128 weeks in males and up to 142 weeks in females), there was no evidence of drug-related carcinogenesis. The highest dose administered in these studies (75 mg/kg/day) was, on a mg/m<sup>2</sup> basis, about equivalent to the maximum recommended daily human oral dose (MRHD) in mice and about twice the MRHD in rats.</paragraph>
                        <paragraph>Combinations of dipyridamole and aspirin (1:5 ratio) tested negative in the Ames test, <content styleCode="italics">in vivo</content> chromosome aberration tests (in mice and hamsters), oral micronucleus tests (in mice and hamsters) and oral dominant lethal test (in mice). Aspirin, alone, induced chromosome aberrations in cultured human fibroblasts. Mutagenicity tests of dipyridamole alone with bacterial and mammalian cell systems were negative.</paragraph>
                        <paragraph>Combinations of dipyridamole and aspirin have not been evaluated for effects on fertility and reproductive performance. There was no evidence of impaired fertility when dipyridamole was administered to male and female rats at oral doses up to 500 mg/kg/day (about 12 times the MRHD on a mg/m<sup>2</sup> basis). A significant reduction in number of corpora lutea with consequent reduction in implantations and live fetuses was, however, observed at 1250 mg/kg (more than 30 times the MRHD on a mg/m<sup>2</sup> basis). Aspirin inhibits ovulation in rats.</paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="5244e31c-dc5d-4c64-b1c5-d77b56a92c4d"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>ESPS2 (European Stroke Prevention Study-2) was a double-blind, placebo-controlled, 24-month study in which 6602 patients over the age of 18 years had an ischemic stroke (76%) or transient ischemic attack (TIA, 24%) within three months prior to entry. Patients were enrolled in 13 European countries between February 1989 and May 1995 and were randomized to one of four treatment groups: AGGRENOX (aspirin/extended-release dipyridamole) 25 mg/200 mg; extended-release dipyridamole (ER-DP) 200 mg alone; aspirin (ASA) 25 mg alone; or placebo. The mean age in this population was 66.7 years with 58% of them being males. Patients received one capsule twice daily (morning and evening). Efficacy assessments included analyses of stroke (fatal or nonfatal) and death (from all causes) as confirmed by a blinded morbidity and mortality assessment group. There were no differences with regard to efficacy based on age or gender; patients who were older had a trend towards more events.</paragraph>
               </text>
               <effectiveTime value="20191219"/>
               <component>
                  <section>
                     <id root="fa1fb1e2-4408-4e21-a865-55ab78a6c4da"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Stroke Endpoint</content>
                        </paragraph>
                        <paragraph>AGGRENOX reduced the risk of stroke by 22.1% compared to aspirin 50 mg/day alone (p = 0.008) and reduced the risk of stroke by 24.4% compared to extended-release dipyridamole 400 mg/day alone (p = 0.002) (Table 3). AGGRENOX reduced the risk of stroke by 36.8% compared to placebo (p &lt;0.001).</paragraph>
                        <table width="100%" ID="table3">
                           <caption>Table 3	Summary of First Stroke (Fatal or Nonfatal): ESPS2: Intent-to-Treat Population</caption>
                           <col width="20%" align="left" valign="top"/>
                           <col width="12%" align="left" valign="top"/>
                           <col width="12%" align="left" valign="top"/>
                           <col width="18%" align="left" valign="top"/>
                           <col width="11%" align="left" valign="top"/>
                           <col width="11%" align="left" valign="top"/>
                           <col width="16%" align="left" valign="top"/>
                           <thead>
                              <tr>
                                 <th/>
                                 <th>Total Number of Patients<br/>n</th>
                                 <th>Number of Patients With Stroke Within 2 Years<br/>n (%)</th>
                                 <th>Kaplan-Meier Estimate of Survival at 2 Years<br/>(95% C.I.)</th>
                                 <th>Gehan-Wilcoxon Test<br/>P-value</th>
                                 <th>Risk Reduction at 2 Years</th>
                                 <th>Odds Ratio<br/>(95% C.I.)</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="7">
                                    <sup>a</sup>0.010 &lt;p-value â¤0.050; <sup>b</sup>p-value â¤0.010.</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="7">Note: ER-DP = extended-release dipyridamole 200 mg; ASA = aspirin 25 mg. The dosage regimen for all treatment groups is BID.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td colspan="7">
                                    <content styleCode="bold">Individual Treatment Group</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td>Â Â AGGRENOX</td>
                                 <td>1650</td>
                                 <td align="center">157 (  9.5%)</td>
                                 <td>89.9% (88.4%, 91.4%)</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td>-</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td>Â Â ER-DP </td>
                                 <td>1654</td>
                                 <td align="center">211 (12.8%)</td>
                                 <td>86.7% (85.0%, 88.4%)</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td>-</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td>Â Â ASA</td>
                                 <td>1649</td>
                                 <td align="center">206 (12.5%)</td>
                                 <td>87.1% (85.4%, 88.7%)</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td>-</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td>Â Â Placebo</td>
                                 <td>1649</td>
                                 <td align="center">250 (15.2%)</td>
                                 <td>84.1% (82.2%, 85.9%)</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td>-</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="7">
                                    <content styleCode="bold">Pairwise Treatment Group Comparisons</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td>Â Â AGGRENOX vs. ER-DP </td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td align="center">0.002<sup>b</sup>
                                 </td>
                                 <td align="center">24.4%</td>
                                 <td>0.72 (0.58, 0.90)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td>Â Â AGGRENOX vs. ASA</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td align="center">0.008<sup>b</sup>
                                 </td>
                                 <td align="center">22.1%</td>
                                 <td>0.74 (0.59, 0.92)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td>Â Â AGGRENOX vs. Placebo</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td align="center">&lt;0.001<sup>b</sup>
                                 </td>
                                 <td align="center">36.8%</td>
                                 <td>0.59 (0.48, 0.73)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td>Â Â ER-DP vs. Placebo</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td align="center">0.036<sup>a</sup>
                                 </td>
                                 <td align="center">16.5%</td>
                                 <td>0.82 (0.67, 1.00)</td>
                              </tr>
                              <tr>
                                 <td>Â Â ASA vs. Placebo</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td>-</td>
                                 <td align="center">0.009<sup>b</sup>
                                 </td>
                                 <td align="center">18.9%</td>
                                 <td>0.80 (0.66, 0.97)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">Figure 1   ESPS2: Cumulative Stroke Rate (Fatal or Nonfatal)</content>
                           <br/> Over 24 months of Follow-Up</paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM3"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                     <component>
                        <observationMedia ID="MM3">
                           <text>Figure 1</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="aggrenox-03.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="d3979326-0876-41a5-b60a-54c79ed153e0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Combined Stroke or Death Endpoint</content>
                        </paragraph>
                        <paragraph>In ESPS2, AGGRENOX reduced the risk of stroke or death by 24.2% compared to placebo.</paragraph>
                        <paragraph>AGGRENOX reduced the risk of stroke or death by 12.1% compared to aspirin alone and by 10.3% compared to extended-release dipyridamole alone. These results were not statistically significant.  </paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="bbaa3990-5f25-4a74-980c-b0bafc81ac22"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Death Endpoint</content>
                        </paragraph>
                        <paragraph>The incidence rate of all-cause mortality was 11.3% for AGGRENOX, 11.0% for aspirin alone, 11.4% for extended-release dipyridamole alone and 12.3% for placebo alone. The differences between the AGGRENOX, aspirin alone and extended-release dipyridamole alone treatment groups were not statistically significant. These incidence rates for AGGRENOX and aspirin alone are consistent with previous aspirin studies in stroke and TIA patients.</paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="0c15d3fe-8e41-4a2e-846e-900f03100519"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>AGGRENOX capsules are available as a hard gelatin capsule, with a red cap and an ivory-colored body, containing yellow extended-release pellets incorporating dipyridamole and a round white tablet incorporating immediate-release aspirin. The capsule body is imprinted in red with the Boehringer Ingelheim logo and with "01A".</paragraph>
                  <paragraph>AGGRENOX 25 mg/250 mg capsules are supplied in unit-of-use bottles of 60 capsules (NDC 0597-0001-60).</paragraph>
               </text>
               <effectiveTime value="20191219"/>
               <component>
                  <section>
                     <id root="29e1f1a6-23a3-4e49-8aa1-e9391b600a08"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Store at 25Â°C (77Â°F); excursions permitted to 15Â°-30Â°C (59Â°-86Â°F)</content> [see USP Controlled Room Temperature]. Protect from excessive moisture.</paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="575bac59-dd93-426b-99be-d6e854ede2dc"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information).</paragraph>
               </text>
               <effectiveTime value="20191219"/>
               <component>
                  <section>
                     <id root="c4fa01b5-b737-4c1b-9b5e-4e9daf2f0333"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="bold">Risk of Bleeding</content>
                           </item>
                        </list>
                        <paragraph>Inform patients that as with other antiplatelet agents, there is a general risk of bleeding including intracranial and gastrointestinal bleeding. Inform patients about the signs and symptoms of bleeding, including occult bleeding. Tell patients to notify their physician if they are prescribed any drug which may increase risk of bleeding.</paragraph>
                        <paragraph>Counsel patients who consume three or more alcoholic drinks daily about the bleeding risks involved with chronic, heavy alcohol use while taking aspirin. </paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="61f1ff05-7c11-49c1-bedc-25c779e0aa01"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="bold">Pregnancy</content>
                           </item>
                        </list>
                        <paragraph>Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant during treatment with AGGRENOX <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="5d97fa46-783f-4e52-96ae-2225849348f8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="bold">Headaches</content>
                           </item>
                        </list>
                        <paragraph>Some patients may experience headaches upon treatment initiation; these are usually transient. In case of intolerable headaches, tell patients to contact their physician.</paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="d6fad904-96fd-4b00-8b28-b52afbf1dd1d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="bold">Stress Test</content>
                           </item>
                        </list>
                        <paragraph>Instruct patients who are scheduled to undergo a pharmacologic stress test to tell their healthcare provider that they are taking AGGRENOX.</paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="4fd880ae-2503-4474-9a46-9f1723220bc0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="bold">Dosage and Administration</content>
                           </item>
                        </list>
                        <paragraph>Tell patients that AGGRENOX capsules should be swallowed whole, and not chewed or crushed. If you miss a dose, continue with your next dose on your regular schedule. Do not take a double dose.</paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="7a0f9196-ba78-4610-b996-aaa572caafa1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="bold">Storage</content>
                           </item>
                        </list>
                        <paragraph>Inform patients to protect AGGRENOX from moisture.</paragraph>
                     </text>
                     <effectiveTime value="20191219"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="9960010d-cb7d-42db-9704-f1fa114cb054"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Distributed by:<br/>Boehringer Ingelheim Pharmaceuticals, Inc.<br/>Ridgefield, CT 06877 USA</paragraph>
                  <paragraph>Product and Trademark Licensed from:<br/>Boehringer Ingelheim International GmbH</paragraph>
                  <paragraph>Copyright Â© 2019 Boehringer Ingelheim International GmbH<br/>ALL RIGHTS RESERVED</paragraph>
                  <paragraph>OT1000PL172019</paragraph>
               </text>
               <effectiveTime value="20191219"/>
            </section>
         </component>
         <component>
            <section>
               <id root="92b145e4-b68b-4cd6-8080-e4000ed3abc3"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title>Patient Information</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">AGGRENOX<sup>Â®</sup> (AG-reh-nox)<br/>(aspirin/extended-release dipyridamole)<br/>Capsules</content>
                  </paragraph>
                  <paragraph>Read this Patient Information before you start taking AGGRENOX and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What is AGGRENOX?</content>
                  </paragraph>
                  <paragraph>AGGRENOX is a prescription medicine that contains aspirin and a medicine that is slowly released in your body, called dipyridamole. AGGRENOX is used to lower the risk of stroke in people who have had a "mini-stroke" (transient ischemic attack or TIA) or stroke due to a blood clot.</paragraph>
                  <paragraph>It is not known if AGGRENOX is safe and effective in children. See <content styleCode="bold">"<linkHtml href="#who">Who should not take AGGRENOX?</linkHtml>"</content>
                  </paragraph>
                  <paragraph ID="who">
                     <content styleCode="bold">Who should not take AGGRENOX?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not take AGGRENOX</content> if you:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>are allergic to any of the ingredients in AGGRENOX. See the end of this leaflet for a list of ingredients in AGGRENOX.</item>
                     <item>are allergic to non-steroidal anti-inflammatory drugs (NSAIDs)</item>
                     <item>have asthma in combination with runny nose and nasal polyps</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Do not give AGGRENOX to a child or teenager with a viral illness. Reye syndrome, a life-threatening condition, can happen when aspirin (an ingredient in AGGRENOX) is used in children and teenagers who have certain viral illnesses.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What should I tell my doctor before using AGGRENOX?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Before taking AGGRENOX, tell your healthcare provider if you:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>have stomach ulcers</item>
                     <item>have a history of bleeding problems</item>
                     <item>have heart problems</item>
                     <item>have kidney or liver problems</item>
                     <item>have low blood pressure</item>
                     <item>have myasthenia gravis</item>
                     <item>have any other medical conditions</item>
                     <item>are pregnant or plan to become pregnant. You should not take AGGRENOX during pregnancy without first talking to your healthcare provider. Tell your healthcare provider right away if you become pregnant while taking AGGRENOX.</item>
                     <item>are breast-feeding or plan to breast-feed. AGGRENOX can pass into your milk. Talk to your healthcare provider about the best way to feed your baby if you take AGGRENOX.</item>
                  </list>
                  <paragraph>Tell your doctor you are taking AGGRENOX if you are scheduled to have a stress test for your heart.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Tell your doctor about all the medicines you take,</content> including prescription and non-prescription medicines, vitamins and herbal supplements. AGGRENOX and other medicines may affect each other causing side effects. AGGRENOX may affect the way other medicines work, and other medicines may affect how AGGRENOX works.</paragraph>
                  <paragraph>Especially tell your healthcare provider if you take:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>
                        <content styleCode="bold">a medicine for high blood pressure, irregular heart beat, or heart failure</content>
                     </item>
                     <item>
                        <content styleCode="bold">acetazolamide [Diamox<sup>Â®</sup>]</content>
                     </item>
                     <item>
                        <content styleCode="bold">any blood thinner medicines</content>
                     </item>
                     <item>
                        <content styleCode="bold">warfarin sodium [Coumadin<sup>Â®</sup>, Jantoven<sup>Â®</sup>]</content>
                     </item>
                     <item>
                        <content styleCode="bold">a heparin medicine</content>
                     </item>
                     <item>
                        <content styleCode="bold">anagrelide [Agrylin<sup>Â®</sup>]</content>
                     </item>
                     <item>
                        <content styleCode="bold">a seizure medicine</content>
                     </item>
                     <item>
                        <content styleCode="bold">a medicine for Alzheimer's disease</content>
                     </item>
                     <item>
                        <content styleCode="bold">a water pill</content>
                     </item>
                     <item>
                        <content styleCode="bold">methotrexate sodium [Trexall<sup>Â®</sup>]</content>
                     </item>
                     <item>
                        <content styleCode="bold">aspirin or a non-steroidal anti-inflammatory drug (NSAIDs). You should not take NSAIDs during treatment with AGGRENOX. </content>Using these medicines with AGGRENOX can increase your risk of bleeding.</item>
                     <item>
                        <content styleCode="bold">a medicine for diabetes</content>
                     </item>
                     <item>
                        <content styleCode="bold">probenecid [Probalan<sup>Â®</sup>, Col-Probenecid<sup>Â®</sup>]</content>
                     </item>
                  </list>
                  <paragraph>Ask your healthcare provider or pharmacist if you are not sure if your medicine is one that is listed above. </paragraph>
                  <paragraph>Know the medicines you take. Keep a list of them and show your healthcare provider and pharmacist when you get a new medicine. </paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I take AGGRENOX?</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Take AGGRENOX exactly as prescribed. Your healthcare provider will tell you how many AGGRENOX to take and when to take them.</item>
                     <item>Headaches are not uncommon when you first start taking AGGRENOX, but often lessen as treatment continues. Tell your healthcare provider if you have a severe headache. Your healthcare provider may change the instructions for taking AGGRENOX.</item>
                     <item>Swallow AGGRENOX whole. Do not crush or chew the capsules.</item>
                     <item>You can take AGGRENOX with or without food.</item>
                     <item>
                        <content styleCode="bold underline italics">If you miss a dose, take your next dose at the usual time. Do not take two doses at one time.</content>
                     </item>
                     <item>If you take more AGGRENOX (overdose) than prescribed, call your healthcare provider or Poison Control Center, or get emergency help right away.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Symptoms of an overdose of AGGRENOX include:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>a warm feeling or flushing</item>
                     <item>sweating</item>
                     <item>restlessness</item>
                     <item>weakness or dizziness</item>
                     <item>a fast heart rate</item>
                     <item>ringing in the ears </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What should I avoid while using AGGRENOX?</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>
                        <content styleCode="bold">heavy alcohol use.</content> People who drink three or more alcoholic drinks every day have a higher risk of bleeding during treatment with AGGRENOX, because it contains aspirin.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What are the possible side effects of AGGRENOX? </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">AGGRENOX may cause serious side effects, including:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>
                        <content styleCode="bold">increased risk of bleeding.</content> You may bleed more easily during AGGRENOX treatment, and it may take longer than usual for bleeding to stop. This can include: 							<list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="bold">bleeding into your brain (intracranial hemorrhage).</content> This can be a medical emergency. Get medical help right away if you have any of these symptoms while taking AGGRENOX: 								<list listType="unordered" styleCode="square">
                                 <item>severe headache with drowsiness  </item>
                                 <item>confusion or memory change</item>
                                 <item>pass out (become unconscious)</item>
                              </list>
                           </item>
                           <item>
                              <content styleCode="bold">bleeding in your stomach or intestine.</content>
                              <list listType="unordered" styleCode="square">
                                 <item>stomach pain</item>
                                 <item>heartburn or nausea</item>
                                 <item>vomiting blood or vomit looks like "coffee grounds"</item>
                                 <item>red or bloody stools </item>
                                 <item>black stools that look like tar</item>
                              </list>
                           </item>
                        </list>
                     </item>
                     <item>
                        <content styleCode="bold">new or worsening chest pain in some people with heart disease.</content> Tell your healthcare provider if you have new chest pain or have any change in your chest pain during treatment with AGGRENOX.</item>
                     <item>
                        <content styleCode="bold">liver problems,</content> including increased liver function tests and liver failure. Tell your healthcare provider if you have any of these symptoms of a liver problem while taking AGGRENOX: 							<list listType="unordered" styleCode="square">
                           <item>loss of appetite</item>
                           <item>pale colored stool</item>
                           <item>stomach area (abdomen) pain</item>
                           <item>yellowing of your skin or whites of your eyes</item>
                           <item>dark urine</item>
                           <item>itching</item>
                        </list>
                     </item>
                  </list>
                  <paragraph>Call your healthcare provider right away if you have any of the symptoms listed above.</paragraph>
                  <paragraph>
                     <content styleCode="bold">The most common side effects of AGGRENOX include:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>headache</item>
                     <item>upset stomach</item>
                     <item>diarrhea</item>
                  </list>
                  <paragraph>These are not all the possible side effects of AGGRENOX. Tell your healthcare provider or pharmacist if you have any side effect that bothers you or that does not go away.</paragraph>
                  <paragraph>Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I store AGGRENOX?</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Store AGGRENOX at room temperature 68Â°F to 77Â°F (20Â°C to 25Â°C).</item>
                     <item>Keep AGGRENOX capsules dry.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Keep AGGRENOX and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">General information about AGGRENOX</content>
                  </paragraph>
                  <paragraph>Medicines are sometimes prescribed for purposes other than those listed in the Patient Information. Do not use AGGRENOX for a condition for which it was not prescribed. Do not give AGGRENOX to other people, even if they have the same symptoms that you have. It may harm them.</paragraph>
                  <paragraph>This Patient Information summarizes the most important information about AGGRENOX. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about AGGRENOX that is written for health professionals.  </paragraph>
                  <paragraph>For current prescribing information, scan the code below or for additional information, you may also call Boehringer Ingelheim Pharmaceuticals, Inc. at 1-800-542-6257, or 1-800-459-9906 TTY.</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM4"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the ingredients in AGGRENOX?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Active Ingredients:</content> dipyridamole in an extended-release form and aspirin</paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactive Ingredients:</content> acacia, aluminum stearate, colloidal silicon dioxide, corn starch, dimethicone, hypromellose, hypromellose phthalate, lactose monohydrate, methacrylic acid copolymer, microcrystalline cellulose, povidone, stearic acid, sucrose, talc, tartaric acid, titanium dioxide and triacetin. Each capsule shell contains gelatin, red iron oxide and yellow iron oxide, titanium dioxide, and water.</paragraph>
                  <paragraph>Distributed by:<br/>Boehringer Ingelheim Pharmaceuticals, Inc.<br/>Ridgefield, CT 06877 USA</paragraph>
                  <paragraph>Product and Trademark Licensed from: <br/>Boehringer Ingelheim International GmbH</paragraph>
                  <paragraph>The other brands listed are trademarks of their respective owners and are not trademarks of Boehringer Ingelheim Pharmaceuticals, Inc.</paragraph>
                  <paragraph>Copyright Â© 2019 Boehringer Ingelheim International GmbH<br/>ALL RIGHTS RESERVED</paragraph>
                  <paragraph>Revised: December 2019<br/>OT1000PL172019</paragraph>
               </text>
               <effectiveTime value="20191219"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>qr-code</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="aggrenox-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="g4021d42b-9e03-7394-cde6-27b1f4c7834b">
               <id root="cbc6366a-c400-4784-badf-762596182289"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph ID="p123221025">Aggrenox<br/>(60) 25 mg/200 mg Capsules<br/>NDC: 0597-0001-60</paragraph>
                  <renderMultiMedia referencedObject="g17523461542466898"/>
               </text>
               <effectiveTime value="20191219"/>
               <component>
                  <observationMedia ID="g17523461542466898">
                     <text>aggrenox-trade-carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="aggrenox-trade-carton.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>